News | July 12, 2010

Lantheus Medical Purchases Worldwide Rights for Ablavar

July 12, 2010 – Lantheus Medical Imaging Inc. today announced that it has acquired the balance of the worldwide rights for gadofosveset trisodium, a unique, injectable magnetic resonance angiography (MRA) blood pool imaging agent that it currently markets in the United States as Ablavar. Ablavar is indicated for use in adults with known or suspected peripheral vascular disease to evaluate aortoiliac occlusive disease. Lantheus purchased the worldwide rights in a recent auction of the remaining assets of Epix Pharmaceuticals. The company already owns exclusive rights to Ablavar in the United States, Canada and Australia.

“Obtaining the balance of the worldwide ownership of Ablavar is part of our strategy to broaden our portfolio of medically important diagnostic imaging products,” said Don Kiepert, President and Chief Executive Officer of Lantheus Medical Imaging Inc. “Our goal is to make this novel blood pool imaging agent available to patients and physicians on an expanded basis.”

Ablavar is the first and only blood pool contrast agent approved for magnetic resonance angiography to evaluate aortoiliac occlusive disease (AIOD) in patients with known or suspected peripheral vascular disease. The albumin-binding properties of Ablavar make it designed for vascular imaging, allowing multiple images to be obtained using a single, low dose injection. Ablavar is clinically proven to produce high resolution MRA images, combining both dynamic (first pass) and steady state imaging, resulting in diagnostic accuracy comparable to conventional X-ray angiography, the current standard of care for diagnosing vascular disease such as AIOD.

The compound was formerly marketed as Vasovist outside the United States. Lantheus acquired exclusive rights for Ablavar in the United States, Canada and Australia in April 2009, and the product was launched in the United States in January 2010.

Related Content

Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Patient Complexity, Subspecialization Impact List Prices for Radiologists' Services
News | Business | August 15, 2017
A new study by the Harvey L. Neiman Health Policy Institute finds that patient condition complexity and...
Upcoming radiology conferences, meetings and events.
News | August 14, 2017
ITN maintains a comprehensive listing of radiology specialty meetings on its website at ...
ACR Establishes Education Committee for Patient- and Family-Centered Care
News | Patient Engagement | August 09, 2017
Members of the new Education Committee of the American College of Radiology (ACR) Commission on Patient- and Family-...
ACR Annual Conference on Quality and Safety Offers Strategies for Radiology Practices
News | Business | August 08, 2017
The American College of Radiology (ACR) Annual Conference on Quality and Safety, scheduled for Oct. 13-14 in Boston,...
Sponsored Content | Videos | Business | July 28, 2017
Angelic McDonald, MSRS, CRA, FAHRA, regional director of imaging, Baylor Scott & White Health and the president-e
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Radiation dose tracking in medical imaging is helping increase patient safety by lower X-ray doses.
Feature | Radiation Dose Management | July 26, 2017 | Dave Fornell
Patient X-ray radiation exposure from medical imaging has been a hot topic in radiology the past few years and has pr
Overlay Init